Medtronic Cardiac Rhythm and Heart Failure
Clinical trials sponsored by Medtronic Cardiac Rhythm and Heart Failure, explained in plain language.
A division of Medtronic focused on cardiac rhythm management and heart failure devices.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a new device make pacemaker placement more precise? Results expected Jul 2027 (estimated)
-
Tiny heart pump trial halted early – what went wrong?
Disease control Stopped earlyThis study tested a small, implantable heart pump called the HeartWare MVAD in 11 people with advanced heart failure. The goal was to see if the device could safely help the heart pump blood. However, the trial was stopped early, so we have limited information on how well it work…
Sponsor: Medtronic Cardiac Rhythm and Heart Failure • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Heart device study in india aims to track AF progression
Knowledge-focused Stopped earlyThis study looked at how Medtronic heart devices detect and manage atrial fibrillation (AF) in Indian patients. It tracked whether the condition became persistent over time. The study enrolled 79 people over 55 with heart devices. It was terminated early, so results are limited.
Sponsor: Medtronic Cardiac Rhythm and Heart Failure • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC